Sansure Biotech Inc.

688289

CNE1000043J1

Medical Equipment, Supplies & Distribution

End-of-day quote Shanghai S.E. Other stock markets 23:00:00 11/06/2024 BST			5-day change	1st Jan Change
18.62 ^CNY	+0.16%		-2.56%	-4.76%

06-12	Sansure Biotech's Tuberculosis Diagnostic Kit Gets EU Certification	MT
04-26	Sansure Biotech Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Sansure Biotech Inc. Provides Earnings Guidance for the First Quarter of 2021

April 13, 2021 at 11:34 am

Sansure Biotech Inc. provided earnings guidance for the first quarter of 2021. For the period the company Predicted Performance Increase in first Quarter of 2021.

Latest news about Sansure Biotech Inc.

Sansure Biotech's Tuberculosis Diagnostic Kit Gets EU Certification	06-12	MT
Sansure Biotech Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	04-26	CI
Sansure Biotech's 2023 Profit Drops 81% as Revenue Slumps 84%	02-29	MT
Sansure Biotech Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	02-28	CI
ASEP Medical Holdings Signs JV Agreement with Chinese Medical Diagnostics Co Sansure Biotech Inc.	11-22	MT
Sansure Biotech Secures EU Certification For In Vitro Diagnostic Device	11-15	MT
Sansure Biotech Inc. Reports Earnings Results for the Nine Months Ended September 30, 2023	30/10/23	CI
Tranche Update on Sansure Biotech Inc.'s Equity Buyback Plan announced on October 21, 2022.	10/10/23	CI
Sansure Biotech Inc.'s Equity Buyback announced on October 21, 2022, has closed with 9,865,793 shares, representing 1.7% for CNY 200 million.	08/10/23	CI
Sansure Biotech Gets EU CE certification for 60 products	22/09/23	MT
Certain A Shares of Sansure Biotech Inc. are subject to a Lock-Up Agreement Ending on 28-AUG-2023.	27/08/23	CI
Sansure Biotech Inc. Reports Earnings Results for the Half Year Ended June 30, 2023	16/08/23	CI
Sansure Biotech's Human Papillomavirus Kit Gets EU Registration Certificate	27/07/23	MT
Tranche Update on Sansure Biotech Inc.'s Equity Buyback Plan announced on October 21, 2022.	30/06/23	CI
Sansure Biotech Inc.(SHSE:688289) dropped from Shanghai Stock Exchange Health Care Sector Index	09/06/23	CI
Sansure Biotech Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	25/04/23	CI
Tranche Update on Sansure Biotech Inc.'s Equity Buyback Plan announced on October 21, 2022.	04/04/23	CI
Sansure Biotech Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	27/02/23	CI
Asep Inc. Lower After Signing JV Term Sheet with Leading Chinese Medical Diagnostic Co. Sansure Biotech Inc.	30/01/23	MT
Sansure Biotech Gets Certification for COVID-19 Kit	30/01/23	MT
ASEP Medical Holdings Inc. Signs Joint Venture Term Sheet with Sansure Biotech Inc. in Preparation for the Commercialization of the Sepset(ER) Sepsis Diagnostic Test in China	27/01/23	CI
Tranche Update on Sansure Biotech Inc.'s Equity Buyback Plan announced on October 21, 2022.	02/01/23	CI
Sansure Biotech to Repurchase Up to $28 Million Shares	21/10/22	MT
Sansure Biotech Inc. announces an Equity Buyback for CNY 200 million worth of its shares.	20/10/22	CI
Sansure Biotech Inc. Reports Earnings Results for the Nine Months Ended September 30, 2022	20/10/22	CI

Sansure Biotech Inc is a company mainly engaged in research and development, production and sales of diagnostic reagents and instruments. The Company's diagnostic reagent products are comprised of viral hepatitis series, reproductive tract infection and genetic series, pediatric infection series and nucleic acid blood screening series. The instrument products include automatic nucleic acid detection reaction system construction series and fluorescent polymerase chain reaction (PCR) monitoring and analysis software. The Company also provides related inspection services, including medical inspection and scientific research services which are provided for medical institutions.

Sector

Medical Equipment, Supplies & Distribution

Calendar

26/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Sansure Biotech Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

18.62 CNY

Average target price

25 CNY

Spread / Average Target

+34.26%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Diagnostic & Testing Substances

	1st Jan change	Capi.
SANSURE BIOTECH INC.	-4.76%	1.47B
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.	-2.58%	8.11B
DIASORIN S.P.A.	+7.73%	5.67B
LANTHEUS HOLDINGS, INC.	+29.76%	5.62B
AUTOBIO DIAGNOSTICS CO., LTD.	-15.77%	3.89B
ANDON HEALTH CO., LTD.	+12.42%	2.68B
10X GENOMICS, INC.	-61.85%	2.58B
VITROLIFE AB	-5.50%	2.26B
MYRIAD GENETICS, INC.	+23.09%	2.03B
GUANGZHOU WONDFO BIOTECH CO.,LTD	-9.25%	1.82B

Diagnostic & Testing Substances